Bilateral breast cancers

Nature Reviews Clinical Oncology

Volumn 11, Issue 3, 2014, Pages 157-166

  Narod, Steven A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; TAMOXIFEN;

BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; CHEK2 GENE; CONTRALATERAL BREAST CANCER; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MASTECTOMY; ONCOGENE; ONSET AGE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASTECTOMY; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 84894707739     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.3     Document Type: Review

References (83)

1. Barry, M. & Sacchini, V. When is contralateral mastectomy warranted in unilateral breast cancer? Expert Rev. Anticancer Ther. 11, 1209-1214 (2011).
2. Murphy, J. A., Milner, T. D. & O'Donoghue, J. M. Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol. 14, e262-e269 (2013).
3. Gilbert, A. Why more women are choosing double mastectomies [online], http://edition.cnn.com/2013/03/13/health/double-mastectomy-rates-up/index.html? iref=storysearch (2013).
4. Tuttle, T. M., Habermann, E. B., Grund, E. H., Morris, T. J. & Virnig, B. A. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J. Clin. Oncol. 25, 5203-5209 (2007). (Pubitemid 350232251)
5. King, T. A. et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J. Clin. Oncol. 29, 2158-2164 (2011).
6. Rosenberg, S. M. et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann. Intern. Med. 159, 373-381 (2013).
7. Banelli, B. et al. Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer. Ann. Oncol. 21, 1237-1242 (2010).
8. Kim, M. Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326 (2009).
9. Hartman, M. et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J. Clin. Oncol. 25, 4210-4216 (2007). (Pubitemid 47548560)
10. Schaapveld, M. et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res. Treat. 110, 189-197 (2008). (Pubitemid 351793865)
11. Intra, M. et al. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer 101, 905-912 (2004). (Pubitemid 39100421)
12. Huo, D., Melkonian, S., Rathouz, P. J., Khramtsov, A. & Olopade, O. I. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer 117, 907-915 (2011).
13. Brennan, M. E. et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J. Clin. Oncol. 27, 5640-5649 (2009).
14. King, T. A. et al. Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Ann. Surg. 254, 2-7 (2011).
15. Sorbero, M. E., Dick, A. W., Beckjord, E. B. & Ahrendt, G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann. Surg. Oncol. 16, 1597-1605 (2009).
16. Chen, Y., Thompson, W., Semenciw, R. & Mao, Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol. Biomarkers Prev. 8, 855-861 (1999). (Pubitemid 29508719)
17. National Comprehensive Cancer Network (NCCN) in Breast Cancer NCCN Practice Guidelines in Oncology (ver. 2.2011) binv-16 (NCCN, 2011).
18. Houssami, N., Ciatto, S., Martinelli, F., Bonardi, R. & Duffy, S. W. Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann. Oncol. 20, 1505-1510 (2009).
19. Solin, L. J., Orel, S. G., Hwang, W. T., Harris, E. E. & Schnall, M. D. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J. Clin. Oncol. 26, 386-391 (2008). (Pubitemid 351171689)
20. Cancer Incidence in Five Continents Volume VIII (eds Parkin, D. M. et al.) (International Agency for Research on Cancer, 2002).
21. Rutqvist, L. E. et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J. Natl Cancer Inst. 83, 1299-1306 (1991).
22. Vaittinen, P. & Hemminki, K. Risk factors and age-incidence relationships for contralateral breast cancer. Int. J. Cancer 88, 998-1002 (2000).
23. Kurian, A. W. et al. Second primary breast cancer occurrence according to hormone receptor status. J. Natl Cancer Inst. 101, 1058-1065 (2009).
24. Walsh, T. & King, M. C. Ten genes for inherited breast cancer. Cancer Cell 11, 103-105 (2007). (Pubitemid 46209856)
25. Metcalfe, K. et al. Predictors of contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 104, 1384-1392 (2011).
26. Mavaddat, N. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J. Natl Cancer Inst. 105, 812-822 (2013).
27. Malone, K. E. et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J. Clin. Oncol. 28, 2404-2410 (2010).
28. Narod, S. A. et al. A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers Curr. Oncol. (in press).
29. Graeser, M. K. et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 27, 5887-5892 (2009).
30. Gronwald, J. et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int. J. Cancer 118, 2281-2284 (2006).
31. Phillips, K. A. et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 31, 3091-3099 (2013).
32. Domchek, S. M. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304, 967-975 (2010).
33. Reding, K. W. et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res. Treat. 123, 491-498 (2010).
34. Metcalfe, K. A. et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 122, 2017-2022 (2008). (Pubitemid 351441190)
35. Lodder, L. N. et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res. Treat.73, 97-112 (2002). (Pubitemid 34548153)
36. Evans, D. G. et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res. Treat. 140, 135-142 (2013).
37. Laitman, Y. et al. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers. Clin. Genet. 85, 68-71 (2014).
38. Singer, C. F. et al. Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria. Clin. Genet. 85, 72-75 (2014).
39. Zhang, S. et al. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. Cancer Res. 68, 2154-2157 (2008). (Pubitemid 351521787)
40. Mellemkjaer, L. et al. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study. Br. J. Cancer 98, 728-733 (2008). (Pubitemid 351272614)
41. Broeks, A. et al. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res. Treat. 83, 91-93 (2004). (Pubitemid 38141897)
42. Narod, S. A. Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clin. Genet. 78, 1-7 (2010).
43. Ghoussaini, M. & Pharoah, P. D. Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol. 5, 689-701 (2009).
44. Teraoka, S. N. et al. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study. Breast Cancer Res. 13, R114 (2011).
45. Horn, P. L. & Thompson, W. D. Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am. J. Epidemiol. 128, 309-323 (1998).
46. Reiner, A. S. et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J. Clin. Oncol. 31, 433-439 (2013).
47. Poynter, J. N. et al. Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study. Cancer Causes Control 21, 839-846 (2010).
48. Largent, J. A. et al. Reproductive history and risk of second primary breast cancer: the WECARE study. Cancer Epidemiol. Biomarkers Prev. 16, 906-911 (2007). (Pubitemid 46910090)
49. Knight, J. A. et al. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women's Environmental Cancer and Radiation Epidemiology Study. Am. J. Epidemiol. 169, 962-968 (2009).
50. Figueiredo, J. C. et al. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group. J. Clin. Oncol. 26, 1411-1418 (2008).
51. Brooks, J. D. et al. Body mass index and risk of second primary breast cancer: the WECARE Study. Breast Cancer Res. Treat. 131, 571-580 (2012).
52. Boyd, N. F., Martin, L. J., Yaffe, M. J. & Minkin, S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. 13, 223 (2011).
53. Cil, T. et al. Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. Cancer 115, 5780-5787 (2009).
54. Sandberg, M. E. et al. Change of mammographic density predicts the risk of contralateral breast cancer: a case-control study. Breast Cancer Res. 15, R57 (2013).
55. Vogel, V. G. et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev. Res. (Phila.) 3, 696-706 (2010).
56. Goss, P. E. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res. Treat. 105, 45-53 (2007). (Pubitemid 47524799)
57. Alkner, S. et al. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: results from a controlled randomised trial. Eur. J. Cancer 45, 2496-2502 (2009).
58. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
59. Arpino, G., Bardou, V. J., Clark, G. M. & Elledge, R. M. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 6, R149-R156 (2004).
60. Saltzman, B. S., Malone, K. E., McDougall, J. A., Daling, J. R. & Li, C. I. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res. Treat. 135, 849-855 (2012).
61. Swain, S. M. et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J. Natl Cancer Inst. 96, 516-523 (2004). (Pubitemid 38559575)
62. Arpino, G., Weiss, H. L., Clark, G. M., Hilsenbeck, S. G. & Osborne, C. K. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J. Clin. Oncol. 23, 4687-4694 (2005). (Pubitemid 46224071)
63. Safal, M. et al. Bilateral synchronous breast cancer and HER-2/neu overexpression. Breast Cancer Res. Treat. 72, 195-201 (2002).
64. Bessonova, L., Taylor, T. H., Mehta, R. S., Zell, J. A. & Anton-Culver, H. Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer. Cancer Epidemiol. Biomarkers Prev. 20, 389-396 (2011).
65. Stark, A., Lu, M., Mackowiak, P. & Linden, M. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts. Breast J. 11, 183-187 (2005). (Pubitemid 40664061)
66. Russnes, H. G. et al. Paired distribution of molecular subtypes in bilateral breast carcinomas. Cancer Genet. 204, 96-102 (2011).
67. Coradini, D. et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? J. Cancer 34, 825-830 (1998). (Pubitemid 28248492)
68. Kollias, J. et al. Phenotypic similarities in bilateral breast cancer. Breast Cancer Res. Treat. 85, 255-261 (2004). (Pubitemid 38987260)
69. Weitzel, J. N. et al. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol. Biomarkers Prev. 14, 1534-1538 (2005). (Pubitemid 40807358)
70. Suspitsin, E. N. et al. TP53 mutations in synchronous and metachronous bilateral breast carcinomas. Cancer Genet. Cytogenet. 184, 119-121 (2008). (Pubitemid 351915761)
71. Suspitsin, E. N. et al. Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: possible role of host factors and survival bias. Int. J. Cancer 120, 297-302 (2007). (Pubitemid 44956839)
72. Narod, S. A. Breast cancer in young women. Nat. Rev. Clin. Oncol. 9, 460-470 (2012).
73. Narod, S. A. A model for breast cancer risk based on stem-cell theory. Curr. Oncol. 19, 9-11 (2012).
74. Dontu, G., El-Ashry, D. & Wicha, M. S. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol. Metab. 15, 193-197 (2004). (Pubitemid 38833988)
75. Ruark, E. et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 493, 406-410 (2013).
76. Pal, B. et al. Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. Cell Rep. 3, 411-426 (2013).
77. Narod, S. A. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res. Treat. 128, 581-583 (2011).
78. Brewster, A. M. et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118, 5637-5643 (2012).
79. Herrinton, L. J. et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J. Clin. Oncol. 23, 4275-4286 (2005). (Pubitemid 46207002)
80. Bedrosian, I., Hu, C. Y. & Chang, G. J. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J. Natl Cancer Inst. 102, 401-409 (2010).
81. Tyrer, J., Duffy, S. W. & Cuzick, J. A breast cancer prediction model incorporating familial and personal risk factors. Stat. Med. 23, 1111-1130 (2004). (Pubitemid 38477070)
82. Campbell, H. E., Taylor, M. A., Harris, A. L. & Gray, A. M. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br. J. Cancer 101, 1074-1084 (2009).
83. Wishart, G. C. et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 12, R1 (2010).